Clinical Trial Update: Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating recombinant Factor VIIa BI for on-demand treatment of acute bleeding episodes in Hemophilia A and B has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• recombinant Factor VIIa BI (recombinant Factor VIIa BI)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A, Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2016-10-25